Real-world study confirms Entyvio's safety for ulcerative colitis patients
NCT ID NCT03824561
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 20 times
Summary
This study looked at the long-term safety and effectiveness of the drug vedolizumab (Entyvio) in over 1,100 people with moderate to severe ulcerative colitis. Participants had not responded well to other treatments. The goal was to see how well the drug works and what side effects occur in everyday medical practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ULCERATIVE COLITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Takeda Selected Site
Tokyo, Japan
Conditions
Explore the condition pages connected to this study.